199 related articles for article (PubMed ID: 37819122)
1. Stability of magistral phage preparations before therapeutic application in patients with chronic rhinosinusitis, sepsis, pulmonary, and musculoskeletal infections.
Uyttebroek S; Bessems L; Metsemakers W-J; Debaveye Y; Van Gerven L; Dupont L; Depypere M; Wagemans J; Lavigne R; Merabishvili M; Pirnay J-P; Devolder D; Spriet I; Onsea J
Microbiol Spectr; 2023 Dec; 11(6):e0290723. PubMed ID: 37819122
[TBL] [Abstract][Full Text] [Related]
2. European regulatory aspects of phage therapy: magistral phage preparations.
Verbeken G; Pirnay JP
Curr Opin Virol; 2022 Feb; 52():24-29. PubMed ID: 34801778
[TBL] [Abstract][Full Text] [Related]
3. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
[TBL] [Abstract][Full Text] [Related]
4. Magistral Phage Preparations: Is This the Model for Everyone?
Pirnay JP; Verbeken G
Clin Infect Dis; 2023 Nov; 77(Suppl 5):S360-S369. PubMed ID: 37932120
[TBL] [Abstract][Full Text] [Related]
5. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?
Maciejewska B; Olszak T; Drulis-Kawa Z
Appl Microbiol Biotechnol; 2018 Mar; 102(6):2563-2581. PubMed ID: 29442169
[TBL] [Abstract][Full Text] [Related]
6. Factors determining phage stability/activity: challenges in practical phage application.
Jończyk-Matysiak E; Łodej N; Kula D; Owczarek B; Orwat F; Międzybrodzki R; Neuberg J; Bagińska N; Weber-Dąbrowska B; Górski A
Expert Rev Anti Infect Ther; 2019 Aug; 17(8):583-606. PubMed ID: 31322022
[No Abstract] [Full Text] [Related]
7. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review.
Uyttebroek S; Chen B; Onsea J; Ruythooren F; Debaveye Y; Devolder D; Spriet I; Depypere M; Wagemans J; Lavigne R; Pirnay JP; Merabishvili M; De Munter P; Peetermans WE; Dupont L; Van Gerven L; Metsemakers WJ
Lancet Infect Dis; 2022 Aug; 22(8):e208-e220. PubMed ID: 35248167
[TBL] [Abstract][Full Text] [Related]
8. A Wake-Up Call: We Need Phage Therapy Now.
Moelling K; Broecker F; Willy C
Viruses; 2018 Dec; 10(12):. PubMed ID: 30563034
[TBL] [Abstract][Full Text] [Related]
9. [Phage therapy, an alternative to antibiotic therapy?)].
Reina J; Reina N
Rev Esp Quimioter; 2018 Apr; 31(2):101-104. PubMed ID: 29451376
[TBL] [Abstract][Full Text] [Related]
10. [Bacteriophages in the battle against multidrug resistant bacteria].
van der Meer JWM; Vandenbroucke-Grauls CMJE
Ned Tijdschr Geneeskd; 2018; 162():D2433. PubMed ID: 29600928
[TBL] [Abstract][Full Text] [Related]
11. Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages.
Cisek AA; Dąbrowska I; Gregorczyk KP; Wyżewski Z
Curr Microbiol; 2017 Feb; 74(2):277-283. PubMed ID: 27896482
[TBL] [Abstract][Full Text] [Related]
12. Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study.
Onsea J; Post V; Buchholz T; Schwegler H; Zeiter S; Wagemans J; Pirnay JP; Merabishvili M; D'Este M; Rotman SG; Trampuz A; Verhofstad MHJ; Obremskey WT; Lavigne R; Richards RG; Moriarty TF; Metsemakers WJ
Microbiol Spectr; 2021 Dec; 9(3):e0173621. PubMed ID: 34908439
[TBL] [Abstract][Full Text] [Related]
13. Phage therapy for severe bacterial infections: a narrative review.
Petrovic Fabijan A; Khalid A; Maddocks S; Ho J; Gilbey T; Sandaradura I; Lin RC; Ben Zakour N; Venturini C; Bowring B; Iredell JR
Med J Aust; 2020 Apr; 212(6):279-285. PubMed ID: 31587298
[TBL] [Abstract][Full Text] [Related]
14. Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (
Onsea J; Uyttebroek S; Chen B; Wagemans J; Lood C; Van Gerven L; Spriet I; Devolder D; Debaveye Y; Depypere M; Dupont L; De Munter P; Peetermans WE; van Noort V; Merabishvili M; Pirnay JP; Lavigne R; Metsemakers WJ
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452408
[TBL] [Abstract][Full Text] [Related]
15. The Medicinal Phage-Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation.
Faltus T
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543808
[TBL] [Abstract][Full Text] [Related]
16. Bacteriophages and its applications: an overview.
Sharma S; Chatterjee S; Datta S; Prasad R; Dubey D; Prasad RK; Vairale MG
Folia Microbiol (Praha); 2017 Jan; 62(1):17-55. PubMed ID: 27718043
[TBL] [Abstract][Full Text] [Related]
17. Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria.
Rohde C; Wittmann J; Kutter E
Surg Infect (Larchmt); 2018; 19(8):737-744. PubMed ID: 30256176
[TBL] [Abstract][Full Text] [Related]
18. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
Luong T; Salabarria AC; Roach DR
Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528
[TBL] [Abstract][Full Text] [Related]
19. Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts.
Royer S; Morais AP; da Fonseca Batistão DW
Arch Microbiol; 2021 May; 203(4):1271-1279. PubMed ID: 33474609
[TBL] [Abstract][Full Text] [Related]
20. Phage Therapy in the Twenty-First Century: Facing the Decline of the Antibiotic Era; Is It Finally Time for the Age of the Phage?
Hesse S; Adhya S
Annu Rev Microbiol; 2019 Sep; 73():155-174. PubMed ID: 31185183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
